When measuring testosterone levels, what is the accuracy difference between liquid chromatography‑tandem mass spectrometry and the major immunoassay methods?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 17, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

LC-MS/MS vs Immunoassays: Accuracy Differences in Testosterone Measurement

LC-MS/MS is significantly more accurate than immunoassays for measuring testosterone, particularly at low concentrations (<3.47 nmol/L or <100 ng/dL), where immunoassays systematically overestimate values and show unacceptable variability. 1

Key Accuracy Differences by Concentration Range

At Low Testosterone Levels (Women, Children, Castrated Patients)

The accuracy gap between methods is most pronounced at low concentrations:

  • Immunoassays show considerable dispersal at concentrations typical of women, with variation due to both kit differences and poor precision at these levels 2
  • All five tested immunoassays overestimated testosterone in women and children compared to LC-MS/MS, with positive mean differences across all methods 3
  • In castrated prostate cancer patients, immunoassays measured mean testosterone at 0.672 ± 0.359 nM versus 0.461 ± 0.541 nM by mass spectrometry (P < 0.0001), resulting in 22.1% false "breakthrough" diagnoses versus 13.1% by LC-MS/MS 4
  • Over 60% of samples with testosterone <3.47 nmol/L showed inaccurate results with immunoassays in both directions compared to LC-MS/MS 5

At Normal Male Range

The methods show better concordance but still significant variability:

  • Most immunoassays yield values lower than GC-MS (the reference method related to LC-MS/MS), though concordance improves at male-range concentrations with less heterogeneity 2
  • When 1,133 laboratories measured the same hypogonadal male sample using 14 different assays, values ranged from 45 to 365 ng/dL (1.6 to 12.7 nmol/L) 6
  • Individual immunoassay biases vary: DPC Immulite showed mean difference of -90 ± 9 ng/dL (underestimation), while Bayer Centaur showed +99 ± 11 ng/dL (overestimation) across wide ranges 5
  • Over 60% of samples in the adult male range measured by most methods fell within ±20% of LC-MS/MS values 5

Specific Performance Metrics

Functional Sensitivity

Functional sensitivity at 20% CV varies dramatically between immunoassays:

  • ARCHITECT: 0.14 nmol/L
  • Centaur: 1.23 nmol/L
  • DxI: 0.36 nmol/L
  • E170: 0.77 nmol/L
  • IMMULITE: 3.49 nmol/L

LC-MS/MS achieves lower limits of quantitation (LLOQ) of 0.03 nmol/L, far superior to any immunoassay 7, 8

Method Comparison Data

In preterm infants, the difference is stark:

  • Males: ECLIA median 1.10 ng/mL (IQR 0.90-2.69) vs LC-MS/MS 0.210 ng/mL (IQR 0.164-0.327)
  • Females: ECLIA median 0.95 ng/mL (IQR 0.71-1.18) vs LC-MS/MS 0.026 ng/mL (IQR 0.0112-0.0526)
  • Correlation was weak (ρ < 0.5), with LC-MS/MS showing superior diagnostic accuracy (AUC 0.96 vs 0.715) 9

Clinical Implications

When LC-MS/MS is Essential

Use LC-MS/MS for:

  • Women with suspected hyperandrogenism
  • Children and adolescents
  • Castrated prostate cancer patients monitoring treatment
  • Any testosterone value <3.47 nmol/L (<100 ng/dL)
  • Confirming borderline results from immunoassays

When Immunoassays Are Acceptable

Immunoassays can distinguish eugonadal from hypogonadal adult males if laboratory-specific reference ranges are established and values are clearly in the normal male range (>12 nmol/L) 5, 10

Critical Pitfalls

Avoid these common errors:

  • Never rely on immunoassay results <3.47 nmol/L without LC-MS/MS confirmation 3, 5
  • Do not assume all immunoassays perform equally—functional sensitivity varies 25-fold between platforms 7
  • Beware of false "castration failure" in prostate cancer patients—50% of immunoassay values ≥0.7 nM measured <0.7 nM by mass spectrometry 4
  • Immunoassays are unreliable for free testosterone measurement regardless of concentration 1

Guideline Recommendations

The 2026 EAU guidelines explicitly state that LC-MS/MS is considered the reference method for total testosterone, though high cost limits routine use 1. The 2018 Endocrine Society guidelines recommend using CDC-certified assays or those verified by accuracy-based external quality control programs, acknowledging that liquid chromatography-tandem mass spectrometry generally offers higher specificity, sensitivity, and precision, especially in the low range 6.

For optimal clinical practice: measure testosterone by LC-MS/MS when diagnostic accuracy is critical, particularly at low concentrations; use only high-quality, validated immunoassays with known performance characteristics for routine screening in adult males; and always confirm borderline or unexpected immunoassay results with LC-MS/MS before making treatment decisions.

References

Guideline

recommendations for investigation of hyperandrogenism.

Annales d'endocrinologie, 2010

Guideline

testosterone therapy in men with hypogonadism: an endocrine society clinical practice guideline.

The Journal of clinical endocrinology and metabolism, 2018

Research

Managing testosterone deficiency in primary care: an international expert consensus.

The aging male : the official journal of the International Society for the Study of the Aging Male, 2026

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.